Israeli company Brainsway Ltd., which develops non-invasive treatments using transcranial magnetic stimulation (TMS), will launch its Deep TMS product in the US this month. The device, which is intended for treatment of major depression, won FDA approval earlier this year.
Israeli company BiolineRX, which is currently testing an innovative drug for treating schizophrenia, is planning a financing round, with a $15 million goal. “Calcalist” reports that the round is set to take place before the interim analysis of the clinical trial planned in March.
Israeli company Brainsway, which developed a device called Deep TMS (transcranial magnetic stimulation), for treating various brain-related disorders, has announced a successful trial of its treatment for smoking addiction. 84 percent of subjects in the trial quit smoking after receiving the treatment, of which approx. one-third were still non-smokers after a six month period.
Israeli company Brainsway Ltd. has received approval from the Health Canada for its Deep TMS treatment. The treatment, approved earlier this month by the American FDA, uses transcranial magnetic stimulation for treating people suffering from depression for whom drug treatment was not effective.
Israeli company Brainsway Ltd., which develops innovative devices for treatment of mental disorders using magnetic pulses, has announced that it has received US Food and Drug Administration (FDA) approval for its Deep TMS system. The system uses transcranial magnetic stimulation (TMS) for treating depression in patients who cannot be treated using standard methods.
A team of Israeli researchers from Hadassah Medical Center has achieved a significant breakthrough in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH), a rare, potentially life-threatening disease, which causes paralysis. The team has identified the gene responsible for the condition and developed an experimental treatment which saved the lives of four children suffering from the disease, some of which have also regained the ability to walk.
PolyPid Ltd., an Israeli biotechnology company, announced today positive preliminary results of a first-in-man clinical trial with BonyPid. In the study, BonyPid demonstrated a clear, positive signal of effect in bone recovery processes, on bones with contaminated open fractures.
Israeli company BioControl Medical, which develops implant for treating complex medical conditions, has reported positive results on its FitNeS treatment trial. The device was implanted in five patients, all of which shown a reduction of up to 50 percent in seizures and no side effects.
Israeli company Atox Bio Ltd. has reported a successful clinical trial of its AB103 treatment for Necrotizing Soft-Tissue Infection (NSTI). Financial magazine Globes reports that due to the successful trial, that has shown that the drug was both effective and safe, the company has begun raising millions of dollars. NSTI is a life-threatening bacterial infection with significant morbidity and high mortality rate.
Israeli pharmaceutical company Kamada has announced positive results of its Phase I/II clinical trial of the company’s AAT protein, the active ingredient in its drug Glassia. The results indicate that the drug may halt the progression of the disease and enable the pancreas to continue excreting insulin.